Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner
South China Morning Post ·
Firm’s chairman Kunio Yamada says city’s university research strength and proximity to mainland China are key draws.
Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner
Firm’s chairman Kunio Yamada says city’s university research strength and proximity to mainland China are key draws.
1 sources · 1 articles · updated 2026-11-02 00:30 UTC · business